Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating critical facts inside TransMedics鈥� filings can feel like performing surgery without imaging. FDA approvals, clinical-trial endpoints, and the economics of single-use perfusion sets are scattered across hundreds of pages, while executive stock moves appear moments before major organ-care milestones. That complexity makes TransMedics SEC filings explained simply an urgent need for analysts and clinicians alike.
Stock Titan solves the puzzle with AI that dissects every submission the instant it hits EDGAR. Whether you need a TransMedics annual report 10-K simplified summary or a flagged line-item from the latest TransMedics quarterly earnings report 10-Q filing, our platform translates technical language into plain English. AG真人官方-time alerts surface TransMedics Form 4 insider transactions real-time, while concise notes decode TransMedics 8-K material events explained. Key features:
- AI-powered highlights of clinical data, R&D spend, and PMA supplements
- Instant access to TransMedics insider trading Form 4 transactions and option grants
- Side-by-side TransMedics earnings report filing analysis for trend spotting
- Clear pointers to TransMedics proxy statement executive compensation details
Use these insights to monitor transplant-volume targets, assess reimbursement risks, or track TransMedics executive stock transactions Form 4 before material disclosures. From understanding TransMedics SEC documents with AI to exporting data for valuation models, Stock Titan keeps surgeons, investors, and industry observers a step ahead鈥攏o medical degree required.
American Water Works (AWK) Q2-25 10-Q highlights
Operating revenue climbed 11% YoY to $1.28 bn (H1 +12% to $2.42 bn) on newly implemented rate cases and modest customer growth. Operating income rose 9% to $489 m, but margin slipped 80 bp to 38.3%. Net income improved 4% to $289 m and diluted EPS hit $1.48 (H1 $2.53, +7%).
Cash from operations declined 13% to $632 m, pressured by higher receivables and working-capital swings, while capex remained heavy at $1.28 bn for network modernisation. Long-term debt fell $240 m to $12.28 bn, yet short-term borrowings rose $710 m, leaving total debt at $14.99 bn; equity increased to $10.68 bn.
Regulation & growth: 2025 general rate authorisations add $232 m in annualised revenue across IL, MO, IA, VA, IN, TN & HI; approved infrastructure surcharges add $38 m. Pending filings in KY ($27 m), WV ($48 m) and a multiyear CA request ($63 m in 2027 with potential $111 m thru 2029) could further expand the rate base. First-half interest income of $44 m from the $795 m 10% secured seller note (HOS sale) supports liquidity.
No new material litigation or risk factors were disclosed; management continues to target ~$3 bn annual capex and disciplined regulatory execution to drive long-term earnings and dividend growth.
Orrstown Financial Services (ORRF) President & CEO Thomas R. Quinn Jr. has filed a Form 4 for a 28 Jul 2025 transaction. A Code F line shows 6,598 restricted shares disposed at $34.55 (鈮� $228 k) to cover withholding taxes triggered by vesting; this is not an open-market sale.
Post-transaction, Quinn still holds 8,918 time-vested restricted shares, 30,116 performance-based RSUs, and 86,453 common shares (62,621 jointly with his spouse)鈥攔oughly 125 k shares in total. No derivative securities were traded or granted. The event is routine and does not materially alter insider alignment with shareholders.
FAQ
What is the current stock price of Transmedics Group (TMDX)?
What is the market cap of Transmedics Group (TMDX)?
What is the core technology behind TransMedics Group?
How does the Organ Care System differ from traditional organ preservation methods?
What are the primary benefits of using TransMedics' technology in organ transplantation?
How does TransMedics generate revenue?
What is TransMedics' approach to regulatory compliance?
Who benefits from TransMedics鈥� Organ Care System?
How does TransMedics contribute to advancing transplant technology?
How does TransMedics position itself in a competitive market?
